LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis)

Treatment of relapsed/refractory multiple myeloma (RRMM) is challenging as patients exhaust all available therapies and the disease becomes refractory to standard drug classes. Here we report the final results of LocoMMotion, the first prospective study of real-world clinical practice (RWCP) in trip...

Full description

Bibliographic Details
Authors: Mateos, María-Victoria, Weisel, Katja, De Stefano, Valerio, Goldschmidt, Hartmut, Delforge, Michel, Mohty, Mohamad, Dytfeld, Dominik, Angelucci, Emanuele, Vincent, Laure, Perrot, Aurore, Benjamin, Reuben, Van de Donk, Niels W. C. J., Ocio San Miguel, Enrique María|||0000-0002-5765-0085, Roccia, Tito, Schecter, Jordan M., Koskinen, Silva, Haddad, Imène, Strulev, Vadim, Mitchell, Lada, Buyze, Jozefien
Format: article
Publication Date:2024
Country:España
Institution:Universidad de Cantabria (UC)
Repository:UCrea Repositorio Abierto de la Universidad de Cantabria
Language:English
OAI Identifier:oai:repositorio.unican.es:10902/35928
Online Access:https://hdl.handle.net/10902/35928
Access Level:Open access
id ES_09dcd9104fda663ca8f9395de64e55ac
oai_identifier_str oai:repositorio.unican.es:10902/35928
network_acronym_str ES
network_name_str España
repository_id_str
spelling LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis)Mateos, María-VictoriaWeisel, KatjaDe Stefano, ValerioGoldschmidt, HartmutDelforge, MichelMohty, MohamadDytfeld, DominikAngelucci, EmanueleVincent, LaurePerrot, AuroreBenjamin, ReubenVan de Donk, Niels W. C. J.Ocio San Miguel, Enrique María|||0000-0002-5765-0085Roccia, TitoSchecter, Jordan M.Koskinen, SilvaHaddad, ImèneStrulev, VadimMitchell, LadaBuyze, JozefienTreatment of relapsed/refractory multiple myeloma (RRMM) is challenging as patients exhaust all available therapies and the disease becomes refractory to standard drug classes. Here we report the final results of LocoMMotion, the first prospective study of real-world clinical practice (RWCP) in triple-class exposed (TCE) patients with RRMM, with a median follow-up of 26.4 months (range, 0.1-35.0). Patients (N = 248) had received median 4 prior LOT (range, 2-13) at enrollment. 91 unique regimens were used in index LOT. Overall response rate was 31.9% (95% CI, 26.1-38.0), median progression-free survival (PFS) was 4.6 months (95% CI, 3.9-5.6) and median overall survival was 13.8 months (95% CI, 10.8-17.0). 152 patients (61.3%) had subsequent LOTs with 134 unique regimens, of which 78 were used in first subsequent LOT. Median PFS2 (from start of study through first subsequent LOT) was 10.8 months (95% CI, 8.4-13.0). 158 patients died on study, 67.7% due to progressive disease. Additional subgroup analyses and long-term safety summaries are reported. The high number of RWCP treatment regimens utilized and poor clinical outcomes confirm a lack of standardized treatment for TCE patients with RRMM, highlighting the need for new treatments with novel mechanisms.This study (ClinicalTrials.gov identifier: NCT04035226) was funded by Janssen Research & Development, LLC and Legend Biotech USA Inc. Medical writing support was provided by Andrew Marson and Sarika Pathak Sharma, PhD, of Eloquent Scientific Solutions, and funded by Janssen Global Services, LLC. The authors thank the LocoMMotion study team, including Jonathan Squire, Kensa Hatch, Lorenzo Acciarri, Henrieke Bruin, and Jeannie Kearl.Nature Publishing GroupUniversidad de Cantabria20242024-01-01journal articlehttp://purl.org/coar/resource_type/c_6501NAhttp://purl.org/coar/version/c_be7fb7dd8ff6fe43info:eu-repo/semantics/articlehttps://hdl.handle.net/10902/35928Leukemia, 2024, 38, 2554-2560reponame:UCrea Repositorio Abierto de la Universidad de Cantabriainstname:Universidad de Cantabria (UC)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repositorio.unican.es:10902/359282026-06-02T12:39:31Z
dc.title.none.fl_str_mv LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis)
title LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis)
spellingShingle LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis)
Mateos, María-Victoria
title_short LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis)
title_full LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis)
title_fullStr LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis)
title_full_unstemmed LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis)
title_sort LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis)
dc.creator.none.fl_str_mv Mateos, María-Victoria
Weisel, Katja
De Stefano, Valerio
Goldschmidt, Hartmut
Delforge, Michel
Mohty, Mohamad
Dytfeld, Dominik
Angelucci, Emanuele
Vincent, Laure
Perrot, Aurore
Benjamin, Reuben
Van de Donk, Niels W. C. J.
Ocio San Miguel, Enrique María|||0000-0002-5765-0085
Roccia, Tito
Schecter, Jordan M.
Koskinen, Silva
Haddad, Imène
Strulev, Vadim
Mitchell, Lada
Buyze, Jozefien
author Mateos, María-Victoria
author_facet Mateos, María-Victoria
Weisel, Katja
De Stefano, Valerio
Goldschmidt, Hartmut
Delforge, Michel
Mohty, Mohamad
Dytfeld, Dominik
Angelucci, Emanuele
Vincent, Laure
Perrot, Aurore
Benjamin, Reuben
Van de Donk, Niels W. C. J.
Ocio San Miguel, Enrique María|||0000-0002-5765-0085
Roccia, Tito
Schecter, Jordan M.
Koskinen, Silva
Haddad, Imène
Strulev, Vadim
Mitchell, Lada
Buyze, Jozefien
author_role author
author2 Weisel, Katja
De Stefano, Valerio
Goldschmidt, Hartmut
Delforge, Michel
Mohty, Mohamad
Dytfeld, Dominik
Angelucci, Emanuele
Vincent, Laure
Perrot, Aurore
Benjamin, Reuben
Van de Donk, Niels W. C. J.
Ocio San Miguel, Enrique María|||0000-0002-5765-0085
Roccia, Tito
Schecter, Jordan M.
Koskinen, Silva
Haddad, Imène
Strulev, Vadim
Mitchell, Lada
Buyze, Jozefien
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidad de Cantabria
description Treatment of relapsed/refractory multiple myeloma (RRMM) is challenging as patients exhaust all available therapies and the disease becomes refractory to standard drug classes. Here we report the final results of LocoMMotion, the first prospective study of real-world clinical practice (RWCP) in triple-class exposed (TCE) patients with RRMM, with a median follow-up of 26.4 months (range, 0.1-35.0). Patients (N = 248) had received median 4 prior LOT (range, 2-13) at enrollment. 91 unique regimens were used in index LOT. Overall response rate was 31.9% (95% CI, 26.1-38.0), median progression-free survival (PFS) was 4.6 months (95% CI, 3.9-5.6) and median overall survival was 13.8 months (95% CI, 10.8-17.0). 152 patients (61.3%) had subsequent LOTs with 134 unique regimens, of which 78 were used in first subsequent LOT. Median PFS2 (from start of study through first subsequent LOT) was 10.8 months (95% CI, 8.4-13.0). 158 patients died on study, 67.7% due to progressive disease. Additional subgroup analyses and long-term safety summaries are reported. The high number of RWCP treatment regimens utilized and poor clinical outcomes confirm a lack of standardized treatment for TCE patients with RRMM, highlighting the need for new treatments with novel mechanisms.
publishDate 2024
dc.date.none.fl_str_mv 2024
2024-01-01
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
NA
http://purl.org/coar/version/c_be7fb7dd8ff6fe43
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/10902/35928
url https://hdl.handle.net/10902/35928
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Nature Publishing Group
publisher.none.fl_str_mv Nature Publishing Group
dc.source.none.fl_str_mv Leukemia, 2024, 38, 2554-2560
reponame:UCrea Repositorio Abierto de la Universidad de Cantabria
instname:Universidad de Cantabria (UC)
instname_str Universidad de Cantabria (UC)
reponame_str UCrea Repositorio Abierto de la Universidad de Cantabria
collection UCrea Repositorio Abierto de la Universidad de Cantabria
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403130675855360
score 15,812429

Similar Items